iFlytek Healthcare's 2025 revenue is expected to grow by 25% year-over-year. Chairman Liu Qingfeng: Significant progress has been made in expanding C-end service package operations.

robot
Abstract generation in progress

On March 27, iFlytek Medical (02506.HK) released its performance report for the fiscal year 2025. During the reporting period, the company achieved operating revenue of 915 million yuan, a year-on-year increase of 25%; the annual loss was 65.77 million yuan, significantly narrowing the loss compared to the previous year, with continuous improvement in operational quality.

The financial report shows that iFlytek Medical’s GBC three-end business achieved coordinated development. Among them, the G-end revenue was 469 million yuan, a year-on-year increase of 20%; the B-end revenue was 173 million yuan, a year-on-year increase of 31%; the C-end revenue was 273 million yuan, a year-on-year increase of 29%. The company’s C-end health sector continues to break through, with the second growth curve accelerating its formation.

At the performance briefing on the evening of March 27, Chairman Liu Qingfeng stated that in the past year, the company has made significant progress in exploring C-end service packages and expanding hospital coverage, and it is expected that by 2026, it will further enrich departmental products and cover more regions.

(Author: Dong Pingping)

	 【Disclaimer】【Advertisement】This article only represents the author's personal views and is unrelated to Hexun.com. Hexun.com maintains neutrality regarding the statements and opinions expressed in the article and does not provide any explicit or implicit guarantees regarding the accuracy, reliability, or completeness of the content. Readers are advised to use this information for reference only and assume all responsibility themselves. Email: news_center@staff.hexun.com

Report

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin